TP53 and neoplasm: Further, solid tumors do not accumulate p53 in response to Pol I inhibitors, which could be explained to be inherently depleted of glutamine, highlighting how the metabolic landscape of the tumor microenvironment can deeply influence the therapeutic response to nucleolar function disruptors.